Should You Buy Coherus Oncology, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Coherus Oncology, Inc. (CHRS) occupies a solid middle-ground position with a Quality of Company score of 6.3/10. At the current market price of $1.33, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 1 of 1 CirclFi valuation models project upside for Coherus Oncology, Inc. (CHRS) at $1.33 — the model consensus leans bullish, with a Quality Score of 6.3/10 and Value-Trap risk of 52/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Coherus Oncology, Inc. (CHRS) in 2026?
What Is the Bull Case vs the Bear Case for Coherus Oncology, Inc. (CHRS)?
| Bull case — $6.29 target (+373.1%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +373.1% across 1 bullish models from the current price of $1.33. | No active model flags significant downside for CHRS. The Value Trap score of 52/100 still argues for some caution. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $6.29 (+373.1%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | |
| Industry tailwind: platform technology validation could provide meaningful support for Coherus Oncology, Inc.'s revenue and margin trajectory in the Biotechnology space. |
How Does CHRS Compare to Its Biotechnology Peers?
Valuation data pages: IONS · BRTX · VTGN · PHAT · RLYB · LXRX · ABOS · NRSN · SIGY · EXEL · INCY
Which Other Stocks Score Like CHRS on Quality?
Closest companies to CHRS’s Quality of Company score of 6.3/10, across all industries.
- PLTK — Playtika Holding Corp. (QOC 6.3) · analysis
- ASTS — AST SpaceMobile, Inc. (QOC 6.3) · analysis
- AIOT — PowerFleet, Inc. (QOC 6.3) · analysis
- ECVT — Ecovyst Inc. (QOC 6.3) · analysis
- OSS — One Stop Systems, Inc. (QOC 6.3) · analysis
- LGN — Legence Corp. (QOC 6.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does CHRS Appear In?
So Is Coherus Oncology, Inc. (CHRS) Worth Buying in 2026?
The convergence of 6.3/10 quality, multi-model undervaluation (1/1 bullish, +373.1% median upside), and a median fair value of $6.29 vs. $1.33 current price makes Coherus Oncology, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Coherus Oncology, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CHRS Stock?
Should I buy CHRS stock right now?
Based on CirclFi's multi-model analysis, 1 of 1 models see upside for CHRS at $1.33. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.3/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Coherus Oncology, Inc.?
Key risks include: an elevated Value Trap score of 52/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does CHRS compare to its competitors?
Among Biotechnology peers, CHRS holds a Quality Score of 6.3/10. Comparable companies include IONS (QOC 6.3), BRTX (QOC 6.3), VTGN (QOC 6.3). The relative ranking helps investors identify whether CHRS offers better fundamental quality than alternatives in the same sector.
Is CHRS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CHRS's Quality Score of 6.3/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy CHRS at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $6.29 to $6.29. At $1.33, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CHRS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad